Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : AIC468
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
AiCuris Launches Phase 1 Trial of AIC468 for BK Virus in Transplant Patients
Details : AIC468 is an antiviral agent which aims to treat BK virus (BKV) infections in kidney transplant (KT) recipients, by inhibiting BKV replication.
Product Name : AIC468
Product Type : Other Large Molecule
Upfront Cash : Inapplicable
October 31, 2024
Lead Product(s) : AIC468
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Letermovir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Royalty Pharma
Deal Size : $220.0 million
Deal Type : Acquisition
Details : Prevymis™ (letermovir) was approved by the US FDA in 2017 and by the EMA and Japan’s PMDA in 2018 for prophylaxis of CMV infection and disease in adult CMV-seropositive recipients of an allogeneic hematopoietic stem cell transplant who are at high ri...
Product Name : Prevymis
Product Type : Other Small Molecule
Upfront Cash : $220.0 million
September 06, 2020
Lead Product(s) : Letermovir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Royalty Pharma
Deal Size : $220.0 million
Deal Type : Acquisition
Lead Product(s) : Pritelivir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Receiving Breakthrough Therapy Designation will facilitate AiCuris goal of bringing pritelivir to patients as quickly as possible . Company is now preparing to add a pivotal Phase 3 trial part to the ongoing Phase 2 study in immunocompromised patients.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 06, 2020
Lead Product(s) : Pritelivir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable